<DOC>
	<DOCNO>NCT03074058</DOCNO>
	<brief_summary>The primary objective study establish bioequivalence two different tablet formulation contain BAY77-1931 . The secondary objective study assess safety tolerability , well Investigate plasma lanthanum concentration BAY 77-1931 ODT 500 mg administration .</brief_summary>
	<brief_title>Bioequivalence Study BAY 77-1931 Orally Disintegrating Tablet</brief_title>
	<detailed_description />
	<criteria>Japanese healthy male adult volunteer ( age , 2045 year ; BMI , 17.626.4 kg/m2 ) Regular use medicine include Chinese herbal drug Clinically relevant finding physical examination Subject take study drug appropriately ( e.g . weak bite force , insufficient salivary flow )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>